Treatment of juvenile idiopathic arthritis, paediatric plaque psoriasis, paediatric uveitis
HULIO — MYLAN PHARMS INC, approved 2025-02-05 (BLA761154).
547,369 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.